Crossmark

Development of Novel Olmesartan Medoxomil Loaded Leciplex for Enhanced Oral Bioavailability: Formulation, Histopathological Analysis, and In Vivo Pharmacokinetic Studies

Crossref DOI link: https://doi.org/10.1007/s12247-025-10219-w

Published Online: 2025-11-25

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eid, Hussein M.

Ali, Adel A.

Salama, Alaa H.

Galal, Asmaa F.

Fouad, Shahinaze A.

Moubarak, Ghada Abdelsabour
Funding

Funding for this research was provided by:

Ahram Canadian University
License Information

Text and Data Mining valid from 2025-11-25

Version of Record valid from 2025-11-25
More Information

Article History

Received: 15 June 2025

Accepted: 12 October 2025

First Online: 25 November 2025

Declarations

:

: The in vivo research protocol was approved by the Ahram Canadian University Animal Ethics Committee (permission code: REC2924) in accordance with the guidelines outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

: Authors declare that they have thoroughly reviewed the last version of the manuscript and have provided their consent for its submission for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below